PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF REPLACING PCV13 WITH PCV15 IN THE NATIONAL IMMUNIZATION PROGRAM IN SAUDI ARABIA

被引：0
|
作者：
Huang, M. [1 ]
Weaver, J. [2 ]
Albassam, G. [3 ]
Akel, R. [4 ]
Chhabra, N. [5 ]
Ranjan, S. [5 ]
Gupta, S. [6 ]
Ugrekhelidze, D. [7 ]
机构：
[1] Merck & Co Inc, Merck Res Labs, Rahway, NJ USA
[2] Merck & Co Inc, Rahway, NJ USA
[3] MSD, Riyadh, Saudi Arabia
[4] MSD, Dubai, U Arab Emirates
[5] CHEORS, North Wales, PA USA
[6] CHEORS, Patna, BR, India
[7] MSD, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE562
引用
收藏
页数：2
相关论文
共 50 条
  • [11] COST-EFFECTIVENESS ANALYSIS OF PCV20 3+1 VERSUS PCV15 2+1 VACCINATION OF THE PEDIATRIC POPULATION IN THE NETHERLANDS
    Ta, A.
    Vinand, E.
    Peters, M.
    Cakar, E.
    Ilic, A.
    Perdrizet, J.
    VALUE IN HEALTH, 2024, 27 (12) : S111 - S111
  • [12] THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCV13) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK
    Patel, R.
    Stoykova, B.
    Lloyd, A. C.
    Willingham, J.
    Hollingsworth, R.
    VALUE IN HEALTH, 2009, 12 (07) : A427 - A427
  • [13] A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCV13) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK
    Patel, R.
    Stoykova, B.
    Lloyd, A. C.
    Willingham, J.
    Hollingsworth, R.
    VALUE IN HEALTH, 2009, 12 (07) : A428 - A428
  • [14] Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
    Atwood, Mark
    Beausoleil, Linda
    Breton, Marie-Claude
    Laferriere, Craig
    Sato, Reiko
    Weycker, Derek
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2018, 109 (5-6): : 756 - 768
  • [15] Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
    Mark Atwood
    Linda Beausoleil
    Marie-Claude Breton
    Craig Laferriere
    Reiko Sato
    Derek Weycker
    Canadian Journal of Public Health, 2018, 109 : 756 - 768
  • [16] Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
    Rubin, Jaime L.
    McGarry, Lisa J.
    Strutton, David R.
    Klugman, Keith P.
    Pelton, Stephen I.
    Gilmore, Kristen E.
    Weinstein, Milton C.
    VACCINE, 2010, 28 (48) : 7634 - 7643
  • [17] Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study
    Regev-Yochay, Gili
    Paran, Yael
    Bishara, Jihad
    Oren, Ilana
    Chowers, Michal
    Tziba, Yevgenia
    Istomin, Valery
    Weinberger, Miriam
    Miron, Dan
    Temper, Violeta
    Rahav, Galia
    Dagan, Ron
    VACCINE, 2015, 33 (09) : 1135 - 1142
  • [18] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Perdrizet, Johnna
    Horn, Emily K.
    Nua, Winniefer
    Perez-Peralta, Judith
    Nailes, Jennifer
    Santos, Jaime
    Ong-Lim, Anna
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (04) : 2625 - 2642
  • [19] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Rajeev Dhere
    Vistasp Sethna
    Hitesh Malviya
    Rajeshwari Adhiseshan
    Infectious Diseases and Therapy, 2022, 11 : 1297 - 1299
  • [20] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Dhere, Rajeev
    Sethna, Vistasp
    Malviya, Hitesh
    Adhiseshan, Rajeshwari
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (03) : 1297 - 1299
12345